Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Seneca Biopharm Inc (SNCA)

Seneca Biopharm Inc (SNCA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 28,711
  • Shares Outstanding, K 17,296
  • Annual Sales, $ 10 K
  • Annual Income, $ -16,270 K
  • 60-Month Beta 1.88
  • Price/Sales 2,075.52
  • Price/Cash Flow N/A
  • Price/Book 2.94
Trade SNCA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.52
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/21/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3400 +23.88%
on 04/16/21
1.8900 -12.17%
on 04/06/21
+0.1100 (+7.10%)
since 03/26/21
3-Month
1.0301 +61.15%
on 03/04/21
2.6700 -37.83%
on 03/22/21
+0.3100 (+22.96%)
since 01/27/21
52-Week
0.5001 +231.93%
on 09/24/20
2.6700 -37.83%
on 03/22/21
+0.8868 (+114.69%)
since 04/27/20

Most Recent Stories

More News
Seneca Biopharma Announces Successful Approval of Merger with Leading Biosciences, Inc.

, /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA) ("" or the "Company"), disclosed on , the passing of the final proposal required for approval of the proposed merger between and Leading Biosciences,...

SNCA : 9.9600 (-1.19%)
Seneca Biopharma, Inc. Announces (i) Voting Results from the Special Meeting of Stockholders and (ii) New Special Meeting Date of April 23, 2021

, /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA) ("" or the "Company"), announced the preliminary voting results of its Special Meeting of Stockholders on . At the Special Meeting, asked stockholders...

SNCA : 9.9600 (-1.19%)
Seneca Stockholder Letter

, /PRNewswire/ --

SNCA : 9.9600 (-1.19%)
Seneca Special Meeting Q&A

, /PRNewswire/ -- The management of Seneca Biopharma, Inc. ("") and Leading BioSciences, Inc. ("LBS") have each received inquiries regarding special meeting of stockholders ("Special Meeting") that was...

SNCA : 9.9600 (-1.19%)
Seneca Announces New Special Meeting Date of April 9, 2021

, /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA) (the "Company") today announced that the Company adjourned its special meeting of stockholders scheduled for at , until at , to be held virtually...

SNCA : 9.9600 (-1.19%)
Seneca Biopharma Reports 2020 Yearend Results

, /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need, today reported its financial results...

SNCA : 9.9600 (-1.19%)
Thinking about buying stock in Support.com, Seneca Biopharma, Hall of Fame Resort & Entertainment, Dyadic International, or Stonemor?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SPRT, SNCA, HOFV, DYAI, and STON.

DYAI : 5.37 (+1.90%)
HOFV : 3.10 (+8.77%)
SNCA : 9.9600 (-1.19%)
SPRT : 11.80 (-38.22%)
STON : 2.0400 (+2.00%)
Independent Advisory Firm ISS Recommends Seneca Biopharma, Inc. Stockholders Vote for Proposed Merger and Reverse Stock Split

, /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), today announced that leading independent proxy advisory firm Institutional Shareholder Services, Inc. ("ISS") has recommended that stockholders...

SNCA : 9.9600 (-1.19%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates MGLN, FPRX, FLIR, WDR, HMSY, SNCA; Shareholders are Encouraged to Contact the Firm

, /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

MGLN : 94.62 (unch)
FPRX : 38.00 (+0.03%)
FLIR : 57.34 (-0.31%)
WDR : 24.98 (-0.04%)
HMSY : 36.98 (+0.01%)
SNCA : 9.9600 (-1.19%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds CLGX, VGAC, SNCA, and RNET Shareholders About Its Ongoing Investigations

, /PRNewswire/ --

CLGX : 80.00 (+0.59%)
VGAC : 10.99 (+3.19%)
SNCA : 9.9600 (-1.19%)
RNET : 9.60 (-2.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Seneca Biopharma Inc. is a clinical-stage biopharmaceutical company. It focuses on developing novel treatments for diseases of unmet medical need. Seneca Biopharma Inc., formerly known as Neuralstem Inc, is based in GERMANTOWN, Md.

See More

Key Turning Points

3rd Resistance Point 1.7322
2nd Resistance Point 1.7017
1st Resistance Point 1.6809
Last Price 9.9600
1st Support Level 1.6296
2nd Support Level 1.5991
3rd Support Level 1.5783

See More

Last Price 9.9600
52-Week High 2.6700
Fibonacci 61.8% 1.8411
Fibonacci 50% 1.5851
Fibonacci 38.2% 1.3290
52-Week Low 0.5001

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar